These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10851497)

  • 1. Maintenance of intestinal epithelium structural integrity and mucosal leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine.
    Killion JJ; Bucana CD; Radinsky R; Dong Z; O'Reilly T; Bilbe G; Tarcsay L; Fidler IJ
    Cancer Biother Radiopharm; 1996 Dec; 11(6):363-71. PubMed ID: 10851497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of chemotherapy- or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide.
    Killion JJ; Brown DR; Wilson MR; Lloyd MM; Fidler IJ
    Oncol Res; 1994; 6(8):357-64. PubMed ID: 7894085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
    Maeda M; Knowles RD; Kleinerman ES
    Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional muramyl tripeptide phosphatidylethanolamine administration enhances hepatic immune function and tumor surveillance.
    Karpoff HM; Jarnagin W; Delman K; Fong Y
    Surgery; 2000 Aug; 128(2):213-8. PubMed ID: 10922994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
    Fidler IJ; Fogler WE; Brownbill AF; Schumann G
    J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T; Kleinerman ES
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats.
    Fox LE; King RR; Shi F; Kurzman ID; MacEwen EG; Kubilis PS
    Cancer Biother; 1994; 9(4):329-40. PubMed ID: 7719380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
    Fujimaki W; Griffin JR; Kleinerman ES
    Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The schistosomulicidal activity and the production of IL-1 and TNF-alpha by peritoneal macrophages from infected mice and their potentiation by muramyl tripeptide-phosphatidyl ethanolamine (MTP-PE) treatment.
    Seger M; Gold D; Lengy J; Pauli H; Keisari Y
    Parasite Immunol; 1993 Jun; 15(6):339-47. PubMed ID: 8361776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bacterial translocation in obstructive jaundice by muramyl tripeptide phosphatidylethanolamine in the rat.
    Ding JW; Andersson R; Soltesz VL; Pärsson H; Johansson K; Wang W; Bengmark S
    J Hepatol; 1994 Jun; 20(6):720-8. PubMed ID: 7930471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression.
    Asano T; Fujimaki W; McWatters A; An T; Matsushima K; Kleinerman ES
    Cancer Immunol Immunother; 1993 Nov; 37(6):408-11. PubMed ID: 8242665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation.
    Macková NO; Fedorocko P
    Neoplasma; 1993; 40(6):379-85. PubMed ID: 8289971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
    Kurzman ID; Shi F; Vail DM; MacEwen EG
    Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
    Maeda M; Asano T; Kleinerman ES
    Cancer Immunol Immunother; 1993 Aug; 37(3):203-8. PubMed ID: 8334682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.
    Tanguay S; Bucana CD; Wilson MR; Fidler IJ; von Eschenbach AC; Killion JJ
    Cancer Res; 1994 Nov; 54(22):5882-8. PubMed ID: 7954418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of rat Kupffer cells to tumoricidal cells by the immunomodulator muramyl tripeptide-phosphatidylethanolamine incorporated into the novel drug carrier lactosylated low density lipoprotein.
    van de Water B; van Berkel TJ; Kuiper J
    Mol Pharmacol; 1994 May; 45(5):971-7. PubMed ID: 8190111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.